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Rabiesa b s t r a c t
The results of a serological study examining the antibody responses generated in cats following admin-
istration of a trivalent feline vaccine (feline calicivirus [FCV], feline herpesvirus [FHV] and feline pan-
leucopaenia virus [FPV]; Versifel CVR) in combination with an inactivated rabies vaccine, in
compliance with European Pharmacopoeia requirements to support new product registrations, are pre-
sented.
Nine week old cats were allocated to one of three groups, 10 cats per group. Group 1 received the CVR
vaccine on days 0 and 21, group 2 received the rabies vaccine on day 21 and group 3 received the CVR
vaccine on day 0 and the CVR vaccine reconstituted with the rabies vaccine (i.e., administered simulta-
neously) on day 21. Blood samples were collected from each animal, on days 0, 21, 28, 35, 42 and 49;
and antibody titres determined using haemagglutination inhibition assay or virus neutralisation test.
FHV and FPV antibody responses in the group 3 combination administration were considered non
-inferior to the responses in the group 1 CVR-only at all time points (days 28, 35, 42 and 49). However
for FCV, group 3 was considered non-inferior to the responses in group 1 on days 28, 35 and 42; but
not on day 49. For rabies, group 3 was only considered non-inferior to the responses in group 2 on day
49; an apparent inferiority was observed on days 28, 35 and 42. However, in all cases cats that received
the combination administration seroconverted with antibody titres at a magnitude shown in other
studies to be protective against virulent challenge, and also at a titre deemed adequate by the European
Pharmacopeia monograph 04/2013:0451 (Rabies vaccine [inactivated] for Veterinary use).
In conclusion, the data show that combining these two separate vaccines in one administration has
limited impact on their ability to generate serological responses, and that these responses are still of a
magnitude previously demonstrated to be protective.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The severity of feline calicivirus (FCV), feline herpesvirus (FHV)
and feline panleucopaenia (FPV) infection is such that vaccines to
these agents are considered core feline vaccine requirements [1],
and are often produced as combination products.
Feline calicivirus is a highly infectious pathogen of cats, with a
widespread distribution [2,3]. Studies have shown the prevalence
is broadly related to the number of cats in a speciﬁc location; with,
for example, privately owned animals present in small numbers [4]
having a lower prevalence than those kept in a cat shelter. FCV has
signiﬁcant genetic diversity with the potential to produce multiplestrains, and therefore the range of clinical signs following infection
can be broad [5]. The presence of antibodies, either maternally-
derived or induced through active vaccination, has been demon-
strated to play a role in reducing or eliminating the clinical signs
of FCV challenge [6], but does not prevent infection [7].
Feline herpesvirus infection results in feline viral rhinotrachei-
tis. The virus replicates in the mucosal tissues of the conjunctiva
and upper respiratory tract and can result in a latent state through
infection of neuronal tissue [8]. The presence of latent carrier cats
can lead to the infection of others through reactivation of the virus
and resultant shedding into the environment [9]. Lesions are a
common result of mucosal infection with epithelial necrosis and
immune cell inﬁltration [10]; but other clinical signs can be
observed.
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vore parvovirus [11], infection resulting in systemic disease
through cellular depletion within lymphoid tissues thus causing
immune suppression of the animal. The bone marrow is also
impacted with virus replicating in early progenitor cell lines
thereby affecting virtually all of the myeloid cell populations.
Infection of kittens while in the uterus or in the immediate period
after birth can affect the central nervous system leading to ataxia
and tremors in the neonatal animals. Signiﬁcant mortality result-
ing from FPV infection is found in younger cats, although the virus
affects all age groups [12].
Rabies infection of cats has signiﬁcant mortality unless rapidly
detected or prevented through vaccination, with virus neutralising
antibodies being particularly important in protection [13].
Although rabies is endemic across the world certain areas are des-
ignated as free of the virus; e.g. countries such as the UK, Japan,
Australia and other islands [14]. The disease is spread from
infected animals by saliva through cuts or scratches to the skin,
and has a variable incubation period depending on virus dose
and location of the entry into the host [15]. The rabies virus repli-
cates in either striated muscle or connective tissue at the point of
entry, and from there to peripheral nerves or directly into nervous
tissue. The virus travels to the salivary glands, at which point the
animal is infectious but prior to onset of any clinical signs [16].
In this study we examined whether the combination of a multi-
valent feline vaccine (Versifel CVR) with a feline rabies vaccine
(Vanguard R) impacted their respective efﬁcacy as measured by
serological response when administered to minimum age kittens.
The serological responses of cats administered the combination
were compared to those of cats administered the two vaccines
when given alone.2. Materials and methods
There were three treatment groups (group 1 – Versifel CVR,
group 2 – rabies vaccine (Vanguard R) and group 3 – Versifel
CVR + Vanguard vaccine). Group 1 containing ten animals received
the CVR vaccine on days 0 and day 21, group 2 containing ten ani-
mals received the rabies vaccine on day 21 and group 3 containing
ten animals received the CVR vaccine on day 0 and the CVR vaccine
reconstituted in the rabies vaccine (i.e. administered simulta-
neously) on day 21. On day 3, 30 animals were selected for inclu-
sion in the study. Animals were randomised to Treatment Groups
as per a randomised complete block design with blocking based
on age by a Zoetis Biometrician. The animal age, the vaccine
batches used and the study design was selected using the existing
guidelines for the concurrent administration of immunological vet-
erinary products (EMEA/CVMP.550/02-FINAL). Ten animals per
treatment group allowed testing for non-inferiority using an equiv-
alence limit difference of 2.0 on the logarithm2 scale assuming a
common standard deviation of 1.71 on the logarithm2 scale, 80%
power, and a 0.05 level of signiﬁcance using a 1-sided test. The val-
ues were based on historical values from other Zoetis studies.
The study was run at a Contract Research Organisation (CRO),
and the design was approved by both the Zoetis and CRO institu-
tional ethical review committees, and fulﬁlled all local and national
animal welfare and care regulations.2.1. Animals
Thirty (30) speciﬁed pathogen free cats aged 59–64 days old at
the time of ﬁrst vaccination were enrolled into three groups. Each
animal had a subcutaneously implanted microchip; the last ﬁve
digits of the microchip number were used to identify each animal
for the study. Blood samples collected three weeks prior to studystart showed all cats to be negative to the vaccinal antigens. Fur-
ther samples collected on day 0, prior to vaccination, showed that
all of the 30 animals were sero-negative to FHV and rabies; 29 ani-
mals were sero-negative to FPV) (the seropositive cat was in group
1 – Versifel CVR); 25 animals were sero-negative to FCV) (the sero-
positive animals comprised two animals from group 1 – Versifel
CVR, one animal from group 2 – rabies and two group 3 – Versifel
CVR + rabies animals). For logistical reasons the pre-screening
samples collected on day 0 were not analysed until the completion
of the study, but due to the limited sample volumes obtained dur-
ing the course of the study the decision was taken to not exclude
these animals from subsequent analysis.
To avoid the potential risk of viral shedding from animals vac-
cinated with the live vaccine (groups 1 and 3) to animals vacci-
nated with the killed vaccine (group 2) animals from group 2
were housed in a separate building. Cats had ad libitum access to
water and commercial cat food during the course of the study.
2.2. Vaccine
A commercial batch of Versifel CVR (Zoetis) vaccine against
feline calicivirus (strain F9 106.8 CCID50), feline panleucopaenia
virus (Snow Leopard strain 104.6 CCID50) and feline herpes virus
(strain FVRm 106.3 CCID50), and a minimum titre inactivated mono-
valent rabies vaccine (Vanguard R, Zoetis; Vnukovo-32 strain
2.0 IU/mL), were used as per the design described above. The Ver-
sifel CVR vaccine is lyophilised and requires reconstitution in
either sterile water (group 1 – Versifel CVR) or with the Vanguard
R vaccine (group 3 – Versifel CVR + Rabies) which is supplied as a
liquid formulation. For each vaccination a 1 mL dose was adminis-
tered to cats by the subcutaneous route. On day 0 all treatments
were administered into the left side of the neck and on day 21 into
the right side of the neck.
2.3. Observations and samples
AVeterinaryexaminationwasperformed for eachanimalondays
7 and3. Only animals assessed as being healthy on day 3 were
enrolled. General health observations were carried out daily by a
qualiﬁed technician from day 7 to day 49 inclusive.
Blood samples were collected from the jugular vein of each ani-
mal into 5 mL whole blood tubes containing no anti-coagulant.
Samples were collected pre-vaccination on days 0 and 21 and on
days 28, 35, 42 and 49. The tubes containing the whole blood were
allowed to coagulate for a minimum of one hour at room temper-
ature and then placed in a centrifuge and spun at 3000 rpm for ﬁf-
teen minutes at 4 C. The resulting serum was removed and
divided between two serum tubes to obtain approximately equal
aliquots.
2.4. Laboratory analysis
The serum was analysed at a commercial diagnostic laboratory
using proprietary assays. Haemagglutination Inhibition (HAI) was
used to detect the presence of antibodies to FPV, Virus Neutralisa-
tion Test (VNT) was used to detect the presence of antibodies to
FHV and FCV, and Fluorescent Antibody Neutralisation Test (FAVN)
was used to detect the presence of antibodies to rabies. Brieﬂy, for
the HAI assay (FPV) blood samples were centrifuged, sera removed
and inactivated by heating for 30 min at 56 C. The appropriate FPV
dilution was added to micro-titre plates and twofold dilutions
made in PBS containing 1% BSA, positive and negative controls
are added to appropriate wells. Twofold dilutions of control and
test sera are made across the plate, and the plates are incubated
at room temperature for one hour. A 1% suspension of porcine
red blood cells are added to all wells and incubated. The titre is
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not show haemagglutination. For the VNT assay (FHV and FCV)
blood samples were centrifuged, sera removed and inactivated by
heating for 30 min at 56 C. For each assay control and test plates
are set up; for the control plates EMEM is added to appropriate
micro-titre plate wells, while on the test plates appropriate posi-
tive and negative controls plus test sera are added and twofold
dilutions made down the plate. Stock virus diluted to 100 TCID50
per 50 ll is added and twofold dilutions made down the plate;
plates are incubated for 1 h at 37 C. Following incubation CRFK
cell suspensions are added to each well and plates incubated at
37 C for a further 72 h. The titre of each sample is deﬁned as the
reciprocal of the last dilution showing neutralisation.
2.5. Data analysis
A Zoetis biometrician did the data summaries and analyses. The
individual cat was treated as the experimental unit. The primary
efﬁcacy variables were the antibody titres. All hypothesis tests
were carried out at a 0.05 level of signiﬁcance. Following ﬁrst vac-
cination, data were analysed using a mixed linear model for
repeated measures to determine a one-tailed lower 95% conﬁdence
interval for the difference in the log2 titres between treatment
groups at each time point. The ﬁxed effects in the model were
treatment, time point and treatment by time point. The random
effects in the model were block, block by treatment interaction
(animal term) and residual. Where the lower conﬁdence limit for
the difference was greater than the non-inferiority margin of 2
(on the log2 scale), then group 3 was considered non-inferior to
group 1 and group 2.3. Results
All animals had normal general health observations for the
duration of the study. Where geometric mean antibody titres are
described, the ranges are also given in brackets, where applicable.
The positive pre-screening results from samples collected on
day 0 were unexpected and could be considered erroneous, given
cats were from an accredited breeder with designated SPF units,
regular health screening and no history of vaccination against the
same viral antigens. A deﬁnitive reason for the sero-positivity
could not be elucidated.
3.1. Feline herpes virus
Based on the statistical model used, group 3 (CVR + rabies vac-
cine group administered simultaneously) was considered non-infe-
rior to group 1 (CVR) at all time points. The geometric mean titres
on days 28, 35, 42 and 49 were 0.5, 0.8 (0.5–3), 1.4 (0.5–4) and 2.3
(1–6) for group 1 and 0.5, 2.3 (0.5–8), 3.1 (1–6) and 4.3 (1–8) for
group 3 respectively. The FHV antibodies in group 3 animals were
only slightly numerically higher than in group 1 animals. As
expected no increase in FHV antibodies was observed in group 2
(rabies) animals. Geometric mean antibody titres for the three
groups are shown in Table 1. In previous studies (data not shown)
where cats were challenged with FHV, sera samples obtained threeTable 1
Geometric mean antibody titres, and standard deviation, to FHV by treatment group and
Treatment group Treatment actual Study day
0 21
T01 Versifel CVR 0.5 ± 0 0.5
T02 Vanguard R (rabies) 0.5 ± 0 0.5
T03 Versifel CVR + Vanguard R 0.5 ± 0 0.5weeks after vaccination and immediately prior to challenge gave
geometric antibody titres of 1.0 (1–13); these titres were sufﬁcient
to signiﬁcantly (P = 0.0003) reduce clinical signs compared to sal-
ine controls following challenge with virulent FHV.
3.2. Feline panleucopaenia virus
Based on the statistical model used, group 3 (CVR + rabies) was
considered non-inferior to group 1 (CVR) at all time points. One
animal in group 1 was seronegative at screening (day 23) and
had positive pre-vaccination day 0 titres. The day 0 sample was
re-tested and the same positive result was obtained. However, this
result did not affect the serological response of the animal to the
vaccination. The geometric mean titres on days 28, 35, 42 and 49
were 10240.0, 8914.4 (5120–20,480), 8470.9 (2560–20,480) and
3880.2 (5–20,480) for group 1 and 10240.0, 5487.5 (5120–
20,480), 6731.2 (5120–20,480) and 5120.0 (5120–20,480) for
group 3 respectively. As expected no increase in FPV antibodies
was observed in group 2 (rabies) animals. On day 42, insufﬁcient
serum volume was collected and as a result only ﬁve group 1
and six group 3 animals had FPV antibody test results. However,
this was still sufﬁcient in order to support the non inferiority sta-
tistical model. Geometric mean antibody titres for the three groups
are shown in Table 2. In previous studies (data not shown) where
cats were challenged with FPV, sera samples obtained three weeks
after vaccination and immediately prior to challenge gave a geo-
metric antibody titre of 5793; these titres were sufﬁcient to signif-
icantly reduce leucopenia in vaccinated cats compared to saline
controls following challenge with virulent FPV.
3.3. Feline calicivirus
Based on the statistical model used, group 3 (CVR + rabies) was
considered non-inferior to group 1 (CVR) on days 28, 35 and 42. An
apparent inferiority in group 3 to group 1 was observed on day 49.
The geometric mean titres on days 28, 35, 42 and 49 were 143.9
(28–640), 67.2 (2.5–640), 79.8 (5–640) and 54.6 (2.5–226) for
group 1 and 259.9 (113–640), 105.7 (2.5–640), 69.5 (2.5–640)
and 49.2 (2.5–640) for group 3 respectively. Antibody response
over the ﬁrst 14 days was higher in group 3 compared with group
1. As expected, no increase in FCV antibodies was observed in
group 2 (rabies) animals.
Two of group 1, one of group 2 and two group 3 animals which
were sero-negative at screening and included in the study had posi-
tive titres pre-vaccination on day 0. One group 1 animal and one
group 3 animal, both with positive day 0 titres, did not respond to
vaccination and remained sero-negative. The response observed in
these animalswas similarwhichever vaccination schedulewas used
i.e. whether vaccinated with CVR alone or vaccinated simulta-
neously with CVR and rabies vaccine. Geometric mean antibody
titres for the three groups are shown in Table 3. In previous studies
(data not shown) where cats were challenged with FCV, sera sam-
ples obtained three weeks after vaccination and immediately prior
to challenge gave geometric antibody titres of 5.2 (1–76); these
titres were sufﬁcient to signiﬁcantly (P < 0.0001) reduce clinical
signs compared to saline controls following challenge with virulent
FCV.study day. Cats were vaccinated on days 0 and 21.
28 35 42 49
± 0 0.5 ± 0 0.8 ± 0.9 1.4 ± 1.4 2.3 ± 1.5
± 0 0.5 ± 0 0.5 ± 0 0.5 v 0.5 ± 0
± 0 0.5 ± 0 2.3 ± 2.4 3.1 ± 2.0 4.3 ± 2.2
Table 4
Geometric mean antibody titres, and standard deviation, to rabies by treatment group and study day. Cats were vaccinated on days 0 and 21.
Treatment group Treatment actual Study day
0 21 28 35 42 49
CVR Versifel CVR 0.12 ± 0.00 0.12 ± 0.03 0.13 ± 0.03 0.13 ± 0.02 0.15 ± 0.03 0.12 ± 0.00
Rabies Vanguard R (rabies) 0.12 ± 0.01 0.12 ± 0.00 6.14 ± 5.50 48.3 ± 33.69 34.34 ± 26.82 44.77 ± 21.97
Combined Versifel CVR + Vanguard R 0.12 ± 0.01 0.13 ± 0.05 0.6 ± 1.00 11.59 ± 13.54 35.06 ± 2.02 30.27 ± 55.65
Table 2
Geometric mean antibody titres, and standard deviation, to FPV by treatment group and study day. Cats were vaccinated on days 0 and 21.
Treatment group Treatment actual Study day
0 21 28 35 42 49
CVR Versifel CVR 8.1 ± 99.4 8914.4 ± 5666.8 10,240 ± 0.0 8914.4 ± 6476.3 8470.9 ± 8014.1 3880.2 ± 8738.9
Rabies Vanguard R (rabies) 5.4 ± 1.6 5 ± 0.00 8.7 ± 2.1 5 ± 0.00 5 ± 0.0 5 ± 0.0
Combined Versifel CVR + Vanguard R 5.2 ± 1.7 8317.5 ± 7419.6 10,240 ± 0.0 5487.5 ± 7839.5 6731.2 ± 7931.9 5120 ± 8027.7
Table 3
Geometric mean antibody titres, and standard deviation, to FCV by treatment group and study day. Cats were vaccinated on days 0 and 21.
Treatment group Treatment actual Study day
0 21 28 35 42 49
CVR Versifel CVR 4.8 ± 1.93 88.7 ± 309.5 143.9 ± 301.3 67.2 ± 197.1 79.8 ± 184.6 54.6 ± 82.3
Rabies Vanguard R (rabies) 3.4 ± 1.1 4.5 ± 34.7 3.9 ± 11.9 2.9 ± 2.4 2.7 ± 0.8 2.5 ± 0.0
Combined Versifel CVR + Vanguard R 5.2 ± 1.6 171.5 ± 258.2 259.9 ± 229.3 105.7 ± 286.1 69.5 ± 278.6 49.2 ± 285.5
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Based on the statistical model used, group 3 (CVR + rabies) was
considered non-inferior to group 2 (rabies) on day 49. An apparent
inferiority of group 3 compared to group 2 was observed on days
28, 35 and 42. The geometric mean titres on days 28, 35, 42 and
49 were 6.14 (1.95–17.34), 48.30 (17.74–119.94), 34.34 (14.76–
90.99) and 44.77 (30.13–90.99) for group 2 and 0.60 (0.49–3.38),
11.59 (44.46–39.72), 35.06 (17.34–20.84) and 30.27 (7.06–
190.09) for group 3 respectively. As expected, no increase in rabies
antibodies was observed in group 1 (CVR) animals. On day 42,
insufﬁcient serum volume was collected and as a result only six
group 2 and three group 3 animals had rabies results. The small
sample size resulted in a large standard error which affected the
conﬁdence interval used to calculate non-inferiority. Geometric
mean antibody titres for the three groups are shown in Table 4.4. Discussion
In this paper we evaluated the efﬁcacy of a multivalent feline
vaccine containing herpesvirus, calicivirus and panleucopaenia
virus when administered in combination with a rabies vaccine.
The effect of the combination vaccine on rabies efﬁcacy, and vice
versa, was determined by comparing serological responses to cats
given each vaccine alone. Although the limited sera collected in
speciﬁc instances may have had an impact on the results, the over-
all conclusion is that there is limited negative effect of combining
the two vaccines on their ability to generate serological responses.
Antibody responses to FHV and FPV were not impacted by combin-
ing the two vaccines at any time point, while responses to FCV or
rabies were not impacted at selected sampling time points only.
We have previously demonstrated that the co-administration of
the combination vaccine described herein, together with a new
feline leukaemia vaccine also has no negative impact on either vac-
cine’s efﬁcacy [17]. Although there was no challenge with virulent
viruses in this current series of studies, the antibody titresachieved following vaccination were equivalent to those obtained
in separate challenge efﬁcacy studies with herpesvirus, calicivirus
and panleucopaenia virus in which vaccinated cats were protected;
showing reductions in clinical signs, virus excretion and leucopae-
nia. As the studies performed in the current investigation were to
support a regulatory submission where only serological equiva-
lence is necessary for the procedure, additional investigations on
the minimum protective antibody titres were not performed, but
comparing these data with previous studies provides a high degree
of conﬁdence that the efﬁcacy of the herpesvirus, calicivirus and
panleucopaenia vaccine is not impacted. Antibody responses are
clearly highly variable between animals, and other elements of
the host immune system are also involved [18,19] in (protective)
responses to FCV, FHV and FPV. Examining these aspects of host
responses fell outside the remit of these speciﬁc trials but could
be a future area for investigation.
The only antigen in the current investigation for which there
was possible interference is rabies; in the combined vaccination
group the antibody responses were lower, but were at a titre that
is still considered protective [14]. Other studies [20] investigating
efﬁcacy of combined vaccines have conjectured that antigens
within a host immune system compete for processing by antigen
presenting cells, and thus immune responses are staggered. This
could indeed be the case with responses to rabies in our study.
By day 49 when the last sample was taken, the responses in the
combined group were not inferior to those in the rabies only treat-
ment group.5. Conclusions
This study demonstrates that all cats either seroconverted or
had elevated antibody titres following vaccination with the two
vaccines administered whether alone or in combination. With
the latter, there was no substantial interference by the multivalent
vaccine on rabies efﬁcacy or vice versa. Indeed, for rabies, all vac-
cinated cats seroconverted at a titre deemed sufﬁcient to be pro-
18 S. Wilson et al. / Trials in Vaccinology 4 (2015) 14–18tective by the European Pharmacopeia monograph 04/2013:0451
(Rabies vaccine [inactivated] for Veterinary use). The ability to
combine the two vaccines will be an aid to veterinary practitioners
in the desire to reduce the number of vaccine administrations to
cats.
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